Posted by Michael Wonder on 18 Oct 2022
MSAC finally recommends genomic testing for certain women with breast cancer
18 October 2022 - A third application from Mryriad Genetics seeking the MBS listing of its gene expression profiling test EndoPredict was considered by the MSAC in July.
After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness, cost effectiveness and total cost, the MSAC supported the creation of a new MBS item for the EndoPredict.
The MSAC supported a fee per service of $1,200 benchmarked against the fees of other genomic tests it has supported on the basis of having incremental prognostic value.
